Potential cost savings associated with dose rounding antineoplastic monoclonal agents
Conclusion
Consultation with key physicians regarding the proposed percent reduction resulted in a 10% dose reduction for all cases when utilizing these three agents. Implementation of a dose rounding protocol for bevacizumab, trastuzumab, and cetuximab represents a potentially substantial cost savings at this institution.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Francis, S. M., Heyliger, A., Miyares, M. A., Viera, M. Tags: Original Articles Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Erbitux | Health | Herceptin | Study